Clinical, Diagnostic, and Therapeutic Implications in Psoriasis Associated With Cardiovascular Disease

• Published in: Actas dermo-sifiliográficas (English ed.) 2017-11, Vol.108 (9), p.800-808
• Main Authors: Bonanad, C, González-Parra, E, Rivera, R, Carrascosa, J M, Daudén, E, Olveira, A, Botella-Estrada, R
• Format: Article
• Language: eng ; spa
• Subjects: Age Factors; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - prevention & control; Clinical Trials as Topic; Comorbidity; Humans; Hyperlipidemias - chemically induced; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Incidence; Meta-Analysis as Topic; Metabolic Syndrome - epidemiology; Practice Guidelines as Topic; Prognosis; Psoriasis - diagnosis; Psoriasis - epidemiology; Psoriasis - etiology; Retinoids - adverse effects; Retinoids - therapeutic use; Risk; Tumor Necrosis Factor-alpha - antagonists & inhibitors
• ISSN: 1578-2190
• DOI: 10.1016/j.ad.2016.12.023

In recent years the concept of psoriasis as a systemic disease has gained acceptance due to its association with numerous comorbid conditions, particularly atherosclerosis and cardiovascular disease. Several studies have shown that patients with psoriasis, especially younger patients and those with more severe forms of psoriasis or with psoriatic arthritis, have a higher prevalence of risk factors and metabolic syndrome, as well as an increased risk of major cardiovascular events such as myocardial infarction, cerebrovascular disease, and peripheral arterial disease. Furthermore, it remains unclear which of the current treatments might be more effective in reducing cardiovascular risk in these patients. It is therefore important for dermatologists to be aware of this increased risk, to be able to detect modifiable risk factors early and, when appropriate, refer patients to other specialists for the prevention of major cardiovascular events.